Opus Genetics Inc.: Citizens Analysts See Great Commercial Potential for Opus in the Field of Inherited Retinal Diseases!

Specialist in Inherited Retinal Diseases Opus Genetics Inc. (IRD) [currently listed under the name "Rexahn Pharmaceuticals Inc.” ] is a clinical-stage biopharmaceutical company focused on developing revolutionary gene therapies. The company's core mission is to restore vision and prevent blindness in patients suffering from inherited retinal diseases (IRDs). The primary solution for those affected, who simultaneously represent the company’s core target group, is a one-time, long-lasting AAV-based gene therapy. These innovative treatments are...